Alongside these changes, a key programme—the priority review voucher programme for paediatric rare diseases—also expired. The programme, which was signed into law in 2012, incentivises the development ...

Priority Gold makes acquiring precious metals ... This is reflected in the company’s positive reviews across multiple independent platforms. This includes an A+ rating from the Better Business ...

An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License ...

A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and ...

Priority review is one of the key policies introduced by the CDE to accelerate drug approval. In the registrational trial for patients with NTRK fusion-positive solid tumors, zurletrectinib ...

On April 17, Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD ...

Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Eylea HD eye drug. Regeneron on Thursday said the ...